Primary completion· ClinicalTrials.gov
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advance
[14C]-STX-478 History and Updates
6 events · 2023 – present
Synced daily from openFDA and ClinicalTrials.gov. Last sync: .
0
FDA Approvals
0
Label Revisions
6
Trial Milestones
0
Pivotal Publications
Source: openFDA, ClinicalTrials.gov via AACT, PubMed · Hipa.ai, 2026-07-08Download chart as PNG
This page tracks every FDA action, clinical trial milestone, and major publication for [14C]-STX-478 since 2023, drawn from openFDA, ClinicalTrials.gov, and PubMed.
Upcoming & expected milestones
Past events
2025
Primary completion· ClinicalTrials.gov
A Study of LY4064809 [14C]-STX-478 in Healthy Male Participants
Trial registered· ClinicalTrials.gov
A Study of LY4064809 [14C]-STX-478 in Healthy Male Participants
Trial started· ClinicalTrials.gov
A Study of LY4064809 [14C]-STX-478 in Healthy Male Participants
2023
Trial started· ClinicalTrials.gov
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advance
Trial registered· ClinicalTrials.gov
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advance
Sources
FDA approvals, label revisions, and recalls come from the public openFDA APIs (Drugs@FDA, Drug Label, Drug Enforcement). Drug-safety communications come from the FDA RSS feed. Trial milestones come from ClinicalTrials.gov via the AACT pg dump. Pivotal-publication events come from PubMed, filtered to high-impact journals linked to a Phase 3 trial in our inventory.